Key facts
- It has raised $9.8M; the latest was Early Stage VC ($9.8M) in Nov 2025.
- Notable investors include Agency for Science, Forward Asset Management, Technology and Research.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Honeybear Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Honeybear Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Honeybear Biosciences
Operator of a biotech company intneded to offer new antibody technology for healthcare companies. The company offers drug discovery services, co-nector technology, and tumor-associated research for patients suffering from devastating cancers, enabling clients to enhance their business operations.
- Sector
- Healthcare
- HQ
- Taipei, Taiwan
- Founded
- 2021
- Website
- honeybearbio.com/
- Ownership
- Privately Held (backing)
Honeybear Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Honeybear Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Honeybear Biosciences in its N-PORT filings yet. We sweep new filings monthly.